Design, analysis and reporting of multi-arm trials and strategies to address multiple testing
Author(s) -
Ayodele Odutayo,
Dmitry Gryaznov,
Bethan Copsey,
A. Paul Monk,
Benjamin Speich,
Corran Roberts,
Karan Vadher,
Peter Dutton,
Matthias Briel,
Sally Hopewell,
Douglas G. Altman
Publication year - 2020
Publication title -
international journal of epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.406
H-Index - 208
eISSN - 1464-3685
pISSN - 0300-5771
DOI - 10.1093/ije/dyaa026
Subject(s) - bonferroni correction , type i and type ii errors , protocol (science) , multiple comparisons problem , medicine , clinical trial , false discovery rate , test strategy , test (biology) , statistical hypothesis testing , medical physics , statistics , computer science , pathology , alternative medicine , mathematics , paleontology , biochemistry , chemistry , software , biology , gene , programming language
Background It is unclear how multiple treatment comparisons are managed in the analysis of multi-arm trials, particularly related to reducing type I (false positive) and type II errors (false negative). Methods We conducted a cohort study of clinical-trial protocols that were approved by research ethics committees in the UK, Switzerland, Germany and Canada in 2012. We examined the use of multiple-testing procedures to control the overall type I error rate. We created a decision tool to determine the need for multiple-testing procedures. We compared the result of the decision tool to the analysis plan in the protocol. We also compared the pre-specified analysis plans in trial protocols to their publications. Results Sixty-four protocols for multi-arm trials were identified, of which 50 involved multiple testing. Nine of 50 trials (18%) used a single-step multiple-testing procedures such as a Bonferroni correction and 17 (38%) used an ordered sequence of primary comparisons to control the overall type I error. Based on our decision tool, 45 of 50 protocols (90%) required use of a multiple-testing procedure but only 28 of the 45 (62%) accounted for multiplicity in their analysis or provided a rationale if no multiple-testing procedure was used. We identified 32 protocol–publication pairs, of which 8 planned a global-comparison test and 20 planned a multiple-testing procedure in their trial protocol. However, four of these eight trials (50%) did not use the global-comparison test. Likewise, 3 of the 20 trials (15%) did not perform the multiple-testing procedure in the publication. The sample size of our study was small and we did not have access to statistical-analysis plans for the included trials in our study. Conclusions Strategies to reduce type I and type II errors are inconsistently employed in multi-arm trials. Important analytical differences exist between planned analyses in clinical-trial protocols and subsequent publications, which may suggest selective reporting of analyses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom